XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines … – MarketWatch

by admin on July 25, 2013

XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines
MarketWatch
The manuscript, published in the current issue of Sleep Medicine, provides information for physicians determining treatment choices for restless legs syndrome/Willis-Ekbom Disease (RLS/WED) based on the long-term benefits and risks of each major class

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: